Top-News
Biotechnologie Israel

Prothena Corporation News

Aktie
WKN:  A1KAVV ISIN:  IE00B91XRN20 US-Symbol:  PRTA
18,50 €
-0,30 €
-1,60%
06.09.24
Handeln Depot/Watchlist
Aktienanzahl *
45,05 Mio.
Marktkapitalisierung *
826,61 Mio. €
Streubesitz
53,90%
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 29.10.2021

Prothena Corporation News

15.03.23 - PR Newswire
Biotech Sector Working Fast to Combat Alzheimer's Disease Cases That are Set to Explode
Biotech Sector Working Fast to Combat Alzheimer's Disease Cases That are Set to Explode PR Newswire
27.10.22 - GlobeNewswire
Prothena to Report Third Quarter 2022 Financial Results on November 3rd
DUBLIN, Ireland, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-​stage clinical biotechnology company with a robust pipeline of ...
28.09.22 - PR Newswire
Thinking about buying stock in Acumen Pharmaceuticals, Prothena Corp, Anavex Life Sciences, Ocugen, or OraSure Technologies?
Thinking about buying stock in Acumen Pharmaceuticals, Prothena Corp, Anavex Life Sciences, Ocugen, or OraSure Technologies? PR Newswire
01.09.22 - GlobeNewswire
Prothena to Participate in Upcoming Healthcare Conferences
DUBLIN, Ireland, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-​stage clinical biotechnology company with a robust pipeline of ...
01.09.22 - GlobeNewswire
Prothena Announces Appointment of Biotechnology Industry Leader Helen S. Kim to its Board of Directors
DUBLIN, Ireland, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-​stage clinical biotechnology company with a robust pipeline of ...
08.08.22 - GlobeNewswire
Prothena Reports Second Quarter 2022 Financial Results and Business Highlights
Net cash used in operating and investing activities was $35.5 million in the second quarter and $72.9 million for the first six months of 2022; quarter-​end cash and restricted cash ...
02.08.22 - GlobeNewswire
Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
DUBLIN, Ireland, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-​stage clinical biotechnology company with a robust pipeline of novel ...
01.08.22 - GlobeNewswire
Prothena to Report Second Quarter 2022 Financial Results on August 8th
DUBLIN, Ireland, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-​stage clinical biotechnology company with a robust pipeline of ...
01.07.22 - GlobeNewswire
Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
DUBLIN, Ireland, July 01, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-​stage clinical biotechnology company with a robust pipeline of novel ...
02.06.22 - GlobeNewswire
Prothena to Participate in Jefferies Healthcare Conference
DUBLIN, Ireland, June 02, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-​stage clinical biotechnology company with a robust pipeline of ...
05.05.22 - GlobeNewswire
Prothena Reports First Quarter 2022 Financial Results and Business Highlights
Net cash used in operating and investing activities was $37.4 million in the first quarter; quarter-​end cash and restricted cash position was $544.3 million Advanced PRX012, a ...
28.04.22 - GlobeNewswire
Prothena to Report First Quarter 2022 Financial Results on May 5th
DUBLIN, Ireland, April 28, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-​stage clinical biotechnology company with a robust pipeline of ...
26.04.22 - GlobeNewswire
Prothena Receives FDA Fast Track Designation for PRX012, a Next-Generation Anti-Amyloid Beta Antibody Under Investigation for the Treatment of Alzheimer’s Disease
PRX012 is a potential best-​in-class, subcutaneous anti-​amyloid beta antibody therapy currently in a Phase 1 clinical study for the treatment of Alzheimer’s disease DUBLIN, Ireland, ...
28.03.22 - GlobeNewswire
Prothena Announces FDA Clearance of IND for PRX012, a Subcutaneous Anti-Amyloid Beta Antibody Under Investigation for the Treatment of Alzheimer’s Disease
Prothena has initiated Phase 1 SAD study of PRX012, under investigation for the treatment of Alzheimer’s disease DUBLIN, Ireland, March 28, 2022 (GLOBE NEWSWIRE) -- ...
21.03.22 - GlobeNewswire
Prothena to Participate in Stifel 2022 Virtual CNS Days
DUBLIN, Ireland, March 21, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-​stage clinical biotechnology company with a robust pipeline of ...
16.03.22 - GlobeNewswire
Prothena Presents New Data for Alzheimer’s and Parkinson’s Disease Programs at AD/PD 2022
Oral presentation on preclinical data demonstrates Prothena’s dual Aβ/tau vaccine, for the potential treatment and prevention of Alzheimer’s, generated anti-Aβ and anti-tau antibodies to ...
17.02.22 - GlobeNewswire
Prothena Reports Fourth Quarter and Full Year 2021 Financial Results, and Provides Financial Guidance and Business Highlights
Net cash used in operating and investing activities was $22.8 million in the fourth quarter and net cash provided by operating and investing activities was $92.0 million for the full ...
10.02.22 - GlobeNewswire
Prothena to Report Fourth Quarter and Full Year 2021 Financial Results and Host Webcast Conference Call on February 17, 2022
DUBLIN, Ireland, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-​stage clinical biotechnology company with a robust pipeline of ...
29.11.21 - GlobeNewswire
Prothena to Participate in JMP Securities Hematology and Oncology Summit
DUBLIN, Ireland, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-​stage clinical biotechnology company with a robust pipeline of ...
04.11.21 - GlobeNewswire
Prothena Reports Third Quarter 2021 Financial Results and Business Highlights
Net cash provided by operating and investing activities was $111.9 million in the third quarter and $114.8 million for the first nine months of 2021; Quarter-​end cash and restricted ...

Newssuche

Videos

newspaper
04.09.24 -9,76%
Technical Trading: Zucker Long kurzfristig
Sugar Long Typ: Turbo Open End WKN: VV50DP Hebel: 5,06 Laufzeit: OpenEnd Einstieg: Market ... Mehr »